Cytochroma makes board appointment
This article was originally published in Scrip
Cytochroma (Canada), a clinical stage speciality pharmaceutical company, has appointed Ulrik Spork to its board of directors. Mr Spork will represent Novo on the company's board and succeeds Dr Søren Schifter, who is leaving Novo. As senior partner, Mr Spork led the establishment of venture investment activities by Novo from its inception in 1999. Before that, he was director of corporate development at Novo Nordisk.